Status message

Active context: kki_bg_colors_yellow

Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber syndrome

Principal Investigator:

The primary objective of this study is to determine the tolerability and optimal dose of cannabidiol (CBD) as an adjunct treatment in children and young adults with Sturge-Weber syndrome and drug resistant epilepsy. To begin to assess this we will do a small expanded access study with 5 subjects with medically refractory seizures and Sturge-Weber syndrome (SWS). We will assess safety and impact on their seizure frequency and severity (as measured by seizure length).

Kennedy Krieger Institute Announces Retirement of President and CEO

Dr. Gary W. GoldsteinThe Institute’s board of directors is conducting a national search and is expected to name a new CEO in the coming months.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.